DCC-2036: A Novel Switch Pocket Inhibitor of ABL Tyrosine Kinase with Therapeutic Efficacy Against BCR-ABL T315I In Vitro and in a CML Mouse Model.
RA Van Etten, WW Chan, VM Zaleskas, P Evangelista… - Blood, 2007 - Elsevier
Therapy with ATP-competitive ABL kinase inhibitors, including imatinib (Gleevec), dasatinib
(Sprycel), and nilotinib (Tasigna), has revolutionized the treatment of chronic myeloid …
(Sprycel), and nilotinib (Tasigna), has revolutionized the treatment of chronic myeloid …
[引用][C] DCC-2036: a novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T315I in vitro and in a CML mouse model
RA VAN ETTEN - Blood, 2007 - cir.nii.ac.jp
DCC-2036 : a novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy
against BCR-ABL T315I in vitro and in a CML mouse model | CiNii Research CiNii 国立情報学 …
against BCR-ABL T315I in vitro and in a CML mouse model | CiNii Research CiNii 国立情報学 …
DCC-2036: A Novel Switch Pocket Inhibitor of ABL Tyrosine Kinase with Therapeutic Efficacy Against BCR-ABL T315I In Vitro and in a CML Mouse Model.
RA Van Etten, WW Chan, VM Zaleskas, P Evangelista… - 2007 - ashpublications.org
Therapy with ATP-competitive ABL kinase inhibitors, including imatinib (Gleevec), dasatinib
(Sprycel), and nilotinib (Tasigna), has revolutionized the treatment of chronic myeloid …
(Sprycel), and nilotinib (Tasigna), has revolutionized the treatment of chronic myeloid …
[引用][C] DCC-2036: A novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T315I in vitro and in a CML mouse model
RA VAN ETTEN - Blood, 2007 - cir.nii.ac.jp
DCC-2036 : A novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy
against BCR-ABL T315I in vitro and in a CML mouse model | CiNii Research CiNii 国立情報学 …
against BCR-ABL T315I in vitro and in a CML mouse model | CiNii Research CiNii 国立情報学 …